Royal Bank Of Canada Reaffirms Outperform Rating for Eagle Pharmaceuticals, Inc. (EGRX)

Royal Bank Of Canada restated their outperform rating on shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) in a report released on Thursday morning, MarketBeat.com reports. Royal Bank Of Canada currently has a $75.00 price objective on the specialty pharmaceutical company’s stock, down from their prior price objective of $81.00.

Other equities analysts have also recently issued reports about the stock. Piper Jaffray Companies reissued a buy rating and issued a $75.00 price objective on shares of Eagle Pharmaceuticals in a research note on Friday, October 27th. ValuEngine raised shares of Eagle Pharmaceuticals from a hold rating to a buy rating in a research note on Monday, October 2nd. Mizuho reissued a sell rating and issued a $37.00 price objective on shares of Eagle Pharmaceuticals in a research note on Wednesday. BidaskClub raised shares of Eagle Pharmaceuticals from a strong sell rating to a sell rating in a research note on Saturday, August 12th. Finally, Zacks Investment Research cut shares of Eagle Pharmaceuticals from a hold rating to a strong sell rating in a research note on Monday, July 31st. Three research analysts have rated the stock with a sell rating and three have given a buy rating to the company. The company presently has a consensus rating of Hold and an average target price of $62.33.

Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) traded up $1.87 during trading hours on Thursday, hitting $55.30. 306,000 shares of the company’s stock were exchanged, compared to its average volume of 330,603. Eagle Pharmaceuticals has a 1-year low of $45.05 and a 1-year high of $97.15. The stock has a market cap of $825.19, a PE ratio of 8.72 and a beta of 1.23. The company has a quick ratio of 3.76, a current ratio of 5.30 and a debt-to-equity ratio of 0.26.

Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported $0.33 EPS for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.18). Eagle Pharmaceuticals had a return on equity of 62.60% and a net margin of 36.95%. The business had revenue of $50.10 million during the quarter, compared to analysts’ expectations of $52.52 million. During the same period in the previous year, the business earned $0.80 earnings per share. The business’s quarterly revenue was up 22.5% on a year-over-year basis. equities research analysts forecast that Eagle Pharmaceuticals will post 3.59 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Royal Bank Of Canada Reaffirms Outperform Rating for Eagle Pharmaceuticals, Inc. (EGRX)” was originally posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.chaffeybreeze.com/2017/11/12/royal-bank-of-canada-reaffirms-outperform-rating-for-eagle-pharmaceuticals-inc-egrx.html.

Eagle Pharmaceuticals announced that its board has initiated a stock buyback program on Wednesday, August 9th that permits the company to repurchase $100.00 million in shares. This repurchase authorization permits the specialty pharmaceutical company to buy up to 13.3% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s management believes its shares are undervalued.

Several institutional investors have recently added to or reduced their stakes in EGRX. Principal Financial Group Inc. lifted its holdings in shares of Eagle Pharmaceuticals by 6.7% in the 1st quarter. Principal Financial Group Inc. now owns 62,036 shares of the specialty pharmaceutical company’s stock worth $5,145,000 after acquiring an additional 3,879 shares during the last quarter. Wellington Management Group LLP bought a new stake in shares of Eagle Pharmaceuticals in the 1st quarter worth about $406,000. FMR LLC lifted its holdings in shares of Eagle Pharmaceuticals by 248.9% in the 1st quarter. FMR LLC now owns 320,992 shares of the specialty pharmaceutical company’s stock worth $26,623,000 after acquiring an additional 228,981 shares during the last quarter. Teachers Advisors LLC lifted its holdings in shares of Eagle Pharmaceuticals by 2.4% in the 1st quarter. Teachers Advisors LLC now owns 15,917 shares of the specialty pharmaceutical company’s stock worth $1,320,000 after acquiring an additional 380 shares during the last quarter. Finally, Legal & General Group Plc lifted its holdings in shares of Eagle Pharmaceuticals by 8.3% in the 1st quarter. Legal & General Group Plc now owns 14,421 shares of the specialty pharmaceutical company’s stock worth $1,196,000 after acquiring an additional 1,104 shares during the last quarter.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Receive News & Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply